Minimally Invasive Clip Supports Tricuspid Valve Repair
By HospiMedica International staff writers Posted on 21 Apr 2020 |
Image: The TriClip transcatheter valve repair device (Photo courtesy of Abbott)
A minimally invasive transcatheter valve repair device offers a new treatment option for those suffering from severe tricuspid regurgitation (TR).
The Abbott (Abbott Park, IL, USA) TriClip System includes three components: the TriClip device itself, a cobalt-chromium clip coated in polyester to promote tissue growth, which clamps to the leaflets of the tricuspid valve, holding them together; a steerable guide catheter that adapts to the right side of the heart; and the percutaneous venous access delivery system, which includes the clip, attached to a highly maneuverable delivery catheter, with all controls at the proximal end. The TriClip is available in two different sizes (NT and XT) to accommodate different patient anatomies.
The device is delivered to the heart through the femoral vein in the leg and works by clipping together a portion of the leaflets of the tricuspid valve in order to reduce blood backflow. This allows the heart to pump blood more efficiently, relieving symptoms of TR and improving the patient's quality of life. In addition, since the heart beats normally during the procedure, the procedure does not require a heart-lung bypass machine. The TriClip System has received the European Community (CE) Mark of approval.
“Tricuspid regurgitation is a highly prevalent, yet seldom treated disease, which is why this approval is a significant milestone for the healthcare community. TriClip has the potential to fill a treatment gap and transform how doctors are able to help people with tricuspid regurgitation,” said Michael Dale, senior vice president of Abbott's structural heart business. “Our clip-based technology provides clinicians a life-changing, proven safe, simple, and effective option to treat people suffering from a crippling and life-threatening disease.”
“Patients suffering from severe tricuspid regurgitation are extremely ill and have very few treatment options,” said Professor Georg Nickenig, MD, PhD, chief of the department of cardiology at University Hospital Bonn (Germany), and lead investigator of the TRILUMINATE trial, which generated strong data that helped lead to the CE Mark of TriClip. “Abbott's TriClip could profoundly impact how physicians treat these patients. The therapy is backed by data proving safety and performance, durability, and improved patient quality of life.”
The tricuspid valve separates the right atrium of the heart from the right ventricle, preventing blood from flowing from the ventricle back into the atrium. Diseases of the tricuspid valve are much rarer than those of the mitral valve, its counterpart in the left half of the heart. Tricuspid insufficiency, leading to TR, leads to build-up of blood in the ventricle and the veins causes increased pressure on these organs, resulting in water retention in the legs and abdomen, liver damage, and potential atrial fibrillation (AF). People with TR are typically older and suffer from multiple co-morbidities, making open-heart surgery a high-risk procedure.
The Abbott (Abbott Park, IL, USA) TriClip System includes three components: the TriClip device itself, a cobalt-chromium clip coated in polyester to promote tissue growth, which clamps to the leaflets of the tricuspid valve, holding them together; a steerable guide catheter that adapts to the right side of the heart; and the percutaneous venous access delivery system, which includes the clip, attached to a highly maneuverable delivery catheter, with all controls at the proximal end. The TriClip is available in two different sizes (NT and XT) to accommodate different patient anatomies.
The device is delivered to the heart through the femoral vein in the leg and works by clipping together a portion of the leaflets of the tricuspid valve in order to reduce blood backflow. This allows the heart to pump blood more efficiently, relieving symptoms of TR and improving the patient's quality of life. In addition, since the heart beats normally during the procedure, the procedure does not require a heart-lung bypass machine. The TriClip System has received the European Community (CE) Mark of approval.
“Tricuspid regurgitation is a highly prevalent, yet seldom treated disease, which is why this approval is a significant milestone for the healthcare community. TriClip has the potential to fill a treatment gap and transform how doctors are able to help people with tricuspid regurgitation,” said Michael Dale, senior vice president of Abbott's structural heart business. “Our clip-based technology provides clinicians a life-changing, proven safe, simple, and effective option to treat people suffering from a crippling and life-threatening disease.”
“Patients suffering from severe tricuspid regurgitation are extremely ill and have very few treatment options,” said Professor Georg Nickenig, MD, PhD, chief of the department of cardiology at University Hospital Bonn (Germany), and lead investigator of the TRILUMINATE trial, which generated strong data that helped lead to the CE Mark of TriClip. “Abbott's TriClip could profoundly impact how physicians treat these patients. The therapy is backed by data proving safety and performance, durability, and improved patient quality of life.”
The tricuspid valve separates the right atrium of the heart from the right ventricle, preventing blood from flowing from the ventricle back into the atrium. Diseases of the tricuspid valve are much rarer than those of the mitral valve, its counterpart in the left half of the heart. Tricuspid insufficiency, leading to TR, leads to build-up of blood in the ventricle and the veins causes increased pressure on these organs, resulting in water retention in the legs and abdomen, liver damage, and potential atrial fibrillation (AF). People with TR are typically older and suffer from multiple co-morbidities, making open-heart surgery a high-risk procedure.
Latest Surgical Techniques News
- Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health
- Tiny Robots Made Out Of Carbon Could Conduct Colonoscopy, Pelvic Exam or Blood Test
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery